These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Costs and persistence of carbonic anhydrase inhibitor versus alpha-2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK-GPRD database. Lafuma A; Berdeaux G Curr Med Res Opin; 2008 May; 24(5):1519-27. PubMed ID: 18413015 [TBL] [Abstract][Full Text] [Related]
5. Topical carbonic anhydrase inhibitors: a new perspective in glaucoma therapy. Hiett JA; Dockter CA Optom Clin; 1992; 2(4):97-112. PubMed ID: 1286242 [TBL] [Abstract][Full Text] [Related]
6. [Trusopt--a new form of drug for treating glaucoma]. Izdebska J Klin Oczna; 1997; 99(3):217-20. PubMed ID: 9456571 [TBL] [Abstract][Full Text] [Related]
7. Management of glaucoma: focus on pharmacological therapy. Marquis RE; Whitson JT Drugs Aging; 2005; 22(1):1-21. PubMed ID: 15663346 [TBL] [Abstract][Full Text] [Related]
8. Topical carbonic anhydrase inhibitors: potential adjuvants to glaucoma therapy in the future. Scott BT Optom Vis Sci; 1994 May; 71(5):332-8. PubMed ID: 8065709 [TBL] [Abstract][Full Text] [Related]
13. Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor. Pfeiffer N Surv Ophthalmol; 1997; 42(2):137-51. PubMed ID: 9381367 [TBL] [Abstract][Full Text] [Related]
14. Topical therapies for glaucoma: what family physicians need to know. Lewis PR; Phillips TG; Sassani JW Am Fam Physician; 1999 Apr; 59(7):1871-9, 1882. PubMed ID: 10208706 [TBL] [Abstract][Full Text] [Related]
15. Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: effect on the quality of life of glaucoma patients with drug-related side effects. Nesher R; Ticho U Isr Med Assoc J; 2003 Apr; 5(4):260-3. PubMed ID: 14509130 [TBL] [Abstract][Full Text] [Related]
16. Association of ocular hypotensive medication types with dynamic contour tonometry and Goldmann applanation tonometry measurements in a glaucoma and ocular hypertensive population. Tzamalis A; Kynigopoulos M; Chalvatzis N; Dimitrakos S; Schlote T J Ocul Pharmacol Ther; 2013 Feb; 29(1):41-7. PubMed ID: 23066787 [TBL] [Abstract][Full Text] [Related]
17. [Impact of prostaglandin-F(2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness -- a cross-sectional study on 403 eyes]. Viestenz A; Martus P; Schlötzer-Schrehardt U; Langenbucher A; Mardin CY Klin Monbl Augenheilkd; 2004 Sep; 221(9):753-6. PubMed ID: 15459842 [TBL] [Abstract][Full Text] [Related]
19. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Balfour JA; Wilde MI Drugs Aging; 1997 May; 10(5):384-403. PubMed ID: 9143858 [TBL] [Abstract][Full Text] [Related]
20. [New medical treatments of glaucoma. New strategies?]. Renard JP; May F; Rigal-Sastourne JC; Maurin JF J Fr Ophtalmol; 2001 Dec; 24(10):1095-9. PubMed ID: 11913242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]